文章
醫療新知 > Cellink以3D列印製造腫瘤以對抗癌症 / Cellink Turns to 3D Printing Tumors to Combat Cancer

Cellink以3D列印製造腫瘤以對抗癌症 / Cellink Turns to 3D Printing Tumors to Combat Cancer

24-01-2018

Cellink以3D列印製造腫瘤以對抗癌症

陳智德

 

 

 

Cellink希望能夠用實驗用腫瘤取代大量的動物測試。Cellink

 

 

 

瑞典生物科技公司Cellink設計出生物墨水(biological ink),可被各種不同3D列印機用於製造不同種類的細胞組織,目前正研究以3D列印製造腫瘤以對抗癌症。此將能看到實際上腫瘤如何生長,以及如何對不同治療做出反應。

 

 

Cellink的最新活動已引發3D列印界內外的極大興趣。該公司日前宣布,已與法國公司CTI Biotech簽署合作協議,製造可用於藥品檢測的腫瘤。透過將生物墨水與病患癌細胞混合的方式,在不危害人體健康下進行對腫瘤的深入研究。

 

 

目前Cellink生產生物列印的鼻子及耳朵,用於化妝品與醫學研究,並製造由人體器官細胞組成的立方體,讓研究人員對進行實驗。

 

 

製造新藥對抗癌症既是公眾的優先考慮,但因癌症細胞存活於病患體內,病患並非皆能接受試驗性地服用新藥對抗癌症,使得新藥發展緩慢,並可能會扼殺創新概念,或為他人的進展製造障礙,因此製造用於藥品檢測的腫瘤擁有深遠的意義。

 

 

Cellink盼未來能列印人體器官,儘管該公司承認可能還要再等15~20年。使用生物墨水製造的腫瘤進行測試,能讓研究人員擺脫許多道德問題,並降低此類研究活動的相關成本。

 

 

Cellink希望能夠用實驗用腫瘤取代大量的動物測試,不僅可開發處理癌症腫瘤的新方式,且能讓醫學研究人員對個人化的癌症治療方法展開研究,減少治療造成的副作用。

 

 

該公司創辦人Erik Gatenholm與Hector Martinez Avila也創造售價最低僅10,000美元的組織3D列印機,引發大量的需求。

 

 

 

Cellink Turns to 3D Printing Tumors to Combat Cancer

by | Jan 9, 2018 | 3D Printing, Medical 3D Printing, Science & Technology |

 
 
It may seem counterintuitive, but the Swedish biotech company Cellink is actually fabricating tumors in an effort to combat cancer. The company, which exploded on the scene in 2016, has risen to fame as a result of their biological ink, designed to be used by a variety of 3D printers to create different types of cell tissues. The founders, Erik Gatenholm and Hector Martinez Avila, then went on to create a tissue printing 3D printer that sells for only $10k and the demand has been phenomenal.
 
 
 
The market for bioprinting is expected to triple between 2016 and 2021, to around $1,33 bn.
[Image courtesy of Cellink]
 
 
 

The company has been in the news so often, it’s nearly exhausting trying to keep up, but their latest activity is one that has garnered great interest both in and outside of the 3D printing community. The company announced on Monday that they have signed a partnership with CTI Biotech, a French company based in Lyon, to fabricate tumors that can be used for pharmaceuticals testing. The ability to mix their own inks with cells from patients’ cancers will allow them to produce tumors that can be subjected to intense research without endangering human lives. As Gatenholm explained in an interview with Business Insider Nordic:

 

 

“You will be able to see how a tumor grows and how it would respond to different treatments. It’s a very relevant and a realistic model for research.”

 

 

Cellink sells both the 3D printers and the bio-ink. The printers are priced between $10,000 and $39,000. [Image courtesy of Cellink]

 

 

 

Currently, Cellink produces bioprinted noses and ears for cosmetics and medical research, as well as creating cubes comprised of cells that can allow researchers to experiment with human organ cells. Branching out into the production of tumors is less of a leap and more of an expansion, and the implications are profound. Developing new medicines to combat cancer is both a high priority for the public and something that can only necessarily proceed slowly as the cancer itself lives inside of a person, who cannot simply be subject to any and all ideas about what might combat the disease. This means that a slow, cautious approach can strangle some innovative ideas or simply create interminable roadblocks to the advancement of others.

 

The ability to use bioink to create tumors frees researchers of the many ethical concerns associated with testing as well as reduces the costs associated with such research activities. Currently, a great deal of the medical testing being undertaken to advance cancer treatments occurs on animals, something that Cellink hopes will be able to be replaced with these made-in-the-lab tumors. The driving idea is that not only will new methods of addressing cancerous tumors be able to be developed, but that also medical researchers can begin to explore personalized means of delivering cancer treatments, hopefully with fewer negative side effects.

 

 

 

Cellink’s founders Hector Martinez Avila (left) and Erik Gatenholm (right), with Cellink CCO Ariel Kramer at Nasdaq First North for the IPO. [Image courtesy of Business Insider Nordic]

 

 

 

This effort is part of Cellink’s mission to be a global leader in bioprinting and to change the face of medicine as we know it. In addition, they hope to one day be able to print human organs, although, Gatenholm admits, that possibility is still most likely 15 to 20 years in the future. Interest in their ideas has been strong and confidence in their company continues to grow, as demonstrated by the fact that only 10 months after the company was founded, there was a 1000% oversubscription to their IPO. During their first year, they have already reached profitability, something not common for tech startups.

 

What do you think of this news? Let us know your thoughts; join the discussion of this and other 3D printing topics at 3DPrintBoard.com or share your thoughts below.

 

 

 

文章來自: 物聯網 – 智慧城市 / 3Dprint.com

中: https://www.digitimes.com.tw/iot/article.asp?cat=158&id=0000522680_X9U7ROVH7DAP4D1R7EOV4

ENG : https://3dprint.com/199654/cellink-3d-printing-tumors/

城中活動

2023-02-15 11:00 上午 2023瑜伽班~ 學習篇
2023-02-09 11:00 上午 花藝班情人節篇
2023-02-08 10:00 上午 大雄工作坊 – 紙識做動物

疑難排解

會員註冊


或許你會想看
HR+/HER2- 型 晚期乳癌治療新喜訊!
CDK4/6抑製劑的出現改變了荷爾蒙受體陽性、第二型人類表皮生長因子受體陰性(HR+/HER2-)晚期乳癌治療 […]
港大醫學院發現抑癌基因缺失令乳癌治療失效
香港大學李嘉誠醫學院(港大醫學院)的研究團隊發現,腫瘤抑制基因 AKTIP缺失後會促進管腔型乳癌的生長,並增加 […]
港大生物學家及合作夥伴揭示DNA解旋機制 為癌症治療帶來新曙光
香港大學(港大)生物科學學院翟元樑博士領導的研究團隊,與香港科技大學(科大)和法國居禮研究所的研究員共同發現了 […]
港大醫學院全球首創嶄新中期肝癌「先縮後除」綜合治療方案
香港大學李嘉誠醫學院(港大醫學院)臨床醫學學院外科學系及臨床腫瘤學系團隊發表嶄新的中期肝癌「先縮後除」綜合治療 […]
「國藥」本地註冊難 病人有藥無得用 工聯會促進一步檢視藥物註冊制度
雖然去年 11 月 1 日起,中國獲納入本港新藥註冊的指明參考國家名單,但持有中國當局發出之註冊證明,仍必須持 […]
【全球首例】 英女童接受「鹼基編輯」新療法 奇蹟殲滅癌細胞
英國13歲女童 Alyssa 去年確診患上罕見急性T淋巴細胞白血病(T-ALL),化療及骨髓移植均告無效,接受 […]
HER2乳癌既兇且惡:適當治療控病效果佳 更能保住生活質素
很多女士以為乳癌離自己很遠,但這種女性最常見癌症其實十分普遍,大約每14名女性便有一人會於75歲之前患上乳癌1 […]
慢性淋巴細胞白血病 (CLL) 口服標靶藥 助病人長時間穩定病情
王紹明醫生 中文大學內科及藥物治療學系名譽臨床副教授 「慢性淋巴細胞白血病 (Chronic lymphocy […]
中大全球首證血糖波動不穩的肥胖型糖尿病患者有較高患癌風險 並證實接受一類常用降血壓藥物的糖尿病患者患癌風險則較低
香港中文大學(中大)醫學院利用大數據研究糖尿病患者的患癌風險,首次獲得兩項重要發現。研究團隊發現患有糖尿病並有 […]
中大葉氏家族基金腫瘤學教授陳林教授就職演講「不苦口的良藥」
抗癌治療的副作用為患者帶來巨大的生理和心理壓力,肝膽胰癌症患者更經常因器官受損,比其他癌症患者較易出現相關副作 […]
中大與國際團隊領導肺癌研究 證實Lorlatinib可成為ALK陽性晚期非小細胞肺癌一線治療
香港中文大學(中大)醫學院莫樹錦教授與國際肺癌專家團隊早前針對帶有「間變性淋巴瘤激酶(ALK)基因變異」的晚期 […]
中大研發嶄新治療組合 帶領亞洲策略性抗擊膽管癌
中大研發嶄新治療組合 帶領亞洲策略性抗擊膽管癌 2022年8月8日 1 中大醫學院領導的一項多中心臨床研究發現 […]